Details for New Drug Application (NDA): 011722
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
NDA 011722 describes TENUATE, which is a drug marketed by Sanofi Aventis Us and Nostrum Labs Inc and is included in four NDAs. Additional details are available on the TENUATE profile page.
The generic ingredient in TENUATE is diethylpropion hydrochloride. There are eleven drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the diethylpropion hydrochloride profile page.
The generic ingredient in TENUATE is diethylpropion hydrochloride. There are eleven drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the diethylpropion hydrochloride profile page.
Summary for 011722
| Tradename: | TENUATE |
| Applicant: | Nostrum Labs Inc |
| Ingredient: | diethylpropion hydrochloride |
| Patents: | 0 |
| Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 011722
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 25MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
